Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 23911291)

1.

Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients.

Wang CC, Tseng TC, Wang PC, Lin HH, Kao JH.

J Formos Med Assoc. 2014 Nov;113(11):786-93. doi: 10.1016/j.jfma.2013.06.003. Epub 2013 Aug 1.

PMID:
23911291
2.

Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection.

Wei MJ, Pan XN, Wei KP, Li XH, Liu XL, Zhang XM, Jiang YL, Zhang CY, Shen JK.

Int Immunopharmacol. 2015 Jun 25. pii: S1567-5769(15)00310-0. doi: 10.1016/j.intimp.2015.06.019. [Epub ahead of print]

PMID:
26118632
3.

Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic HBV Infection.

Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, Lee CM.

Clin Gastroenterol Hepatol. 2015 Jun 11. pii: S1542-3565(15)00788-0. doi: 10.1016/j.cgh.2015.06.002. [Epub ahead of print]

PMID:
26073492
4.

Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study.

Nagaoka S, Abiru S, Komori A, Sasaki R, Bekki S, Hashimoto S, Saeki A, Yamasaki K, Migita K, Nakamura M, Ezaki H, Yatsuhashi H.

Hepatol Res. 2015 May 7. doi: 10.1111/hepr.12533. [Epub ahead of print]

PMID:
25951079
5.

Hepatitis B surface antigen seroconversion in HBeAg negative chronic hepatitis B patient during entecavir treatment.

Altun R, Şahintürk H, Şişman G, Baran B.

Turk J Gastroenterol. 2014 Dec;25 Suppl 1:272-3. doi: 10.5152/tjg.2014.5862. No abstract available.

6.

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.

Choi HN, Song JE, Lee HC, Jo HH, Lee CH, Kim BS.

Clin Mol Hepatol. 2015 Mar;21(1):24-31. doi: 10.3350/cmh.2015.21.1.24. Epub 2015 Mar 25.

7.

Nationwide large survey on hepatitis B surface antigen quantification use in real-life clinical practice.

Halfon P, Penaranda G, Mohamed S, Camus C, Khiri H.

Eur J Gastroenterol Hepatol. 2015 May;27(5):557-60. doi: 10.1097/MEG.0000000000000326.

PMID:
25822864
8.

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years.

Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P.

Hepatol Int. 2015 Apr;9(2):243-50. doi: 10.1007/s12072-015-9614-4. Epub 2015 Mar 13.

9.

Reappearance of serum hepatitis B viral DNA in patients with hepatitis B surface antigen seroclearance.

Nakamura M, Kanda T, Nakamoto S, Haga Y, Sasaki R, Jiang X, Yasui S, Arai M, Yokosuka O.

Hepatology. 2015 Jan 8. doi: 10.1002/hep.27693. [Epub ahead of print] No abstract available.

PMID:
25573053
10.

Reactivation of hepatitis B virus 40 months after discontinuation of rituximab maintenance treatment and 5 months after cessation of entecavir administration.

Dai XB, Sun XM, Zhu XJ.

Clin Res Hepatol Gastroenterol. 2015 Jun;39(3):e39-40. doi: 10.1016/j.clinre.2014.11.005. Epub 2014 Dec 30. No abstract available.

PMID:
25556123
11.

Association of serum IgG N-glycome and transforming growth factor-β1 with hepatitis B virus e antigen seroconversion during entecavir therapy.

Ho CH, Chien RN, Cheng PN, Liu CK, Su CS, Wu IC, Liu WC, Chen SH, Chang TT.

Antiviral Res. 2014 Nov;111:121-8. doi: 10.1016/j.antiviral.2014.09.011. Epub 2014 Sep 28.

PMID:
25260899
12.

Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis.

Fung J, Wong DK, Seto WK, Kopaniszen M, Lai CL, Yuen MF.

Am J Gastroenterol. 2014 Nov;109(11):1764-70. doi: 10.1038/ajg.2014.301. Epub 2014 Sep 23.

PMID:
25244963
13.

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.

Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, Brunetto M, Yu S, Llamoso C.

J Hepatol. 2015 Jan;62(1):56-63. doi: 10.1016/j.jhep.2014.08.031. Epub 2014 Aug 28.

PMID:
25176615
14.

Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.

Boglione L, Cardellino CS, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.

J Med Virol. 2014 Nov;86(11):1845-50. doi: 10.1002/jmv.24038. Epub 2014 Aug 8.

PMID:
25131947
15.

Artificial neural network accurately predicts hepatitis B surface antigen seroclearance.

Zheng MH, Seto WK, Shi KQ, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF.

PLoS One. 2014 Jun 10;9(6):e99422. doi: 10.1371/journal.pone.0099422. eCollection 2014.

16.

[Analysis of a randomized, double-blind, double-dummy, controlled, multicenter study confirmed the similar therapeutic efficacies of entecavir maleate and entecavir for treatment of HBeAg-positive chronic hepatitis B].

Xu JH, Yu YY, Si CW, Zeng Z, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J, Xu ZN.

Zhonghua Gan Zang Bing Za Zhi. 2013 Dec;21(12):881-5. doi: 10.3760/cma.j.issn.1007-3418.2013.12.001. Chinese.

PMID:
24636286
17.

Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.

Maklad S, Doss W, El Din SS, Hassan K, Zeid AA.

Arab J Gastroenterol. 2014 Mar;15(1):1-5. doi: 10.1016/j.ajg.2014.01.003. Epub 2014 Feb 4.

PMID:
24630505
18.

Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy.

Huang YW, Hsu CK, Lin SC, Wei SC, Hu JT, Chang HY, Liang CW, Chen DS, Chen PJ, Hsu PN, Yang SS, Kao JH.

Antivir Ther. 2014;19(7):637-43. doi: 10.3851/IMP2762. Epub 2014 Mar 12.

PMID:
24622882
19.

Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.

Boyd A, Maylin S, Gozlan J, Delaugerre C, Simon F, Girard PM, Lacombe K.

Liver Int. 2015 Mar;35(3):795-804. doi: 10.1111/liv.12521. Epub 2014 Mar 31.

PMID:
24606220
20.

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.

Seto WK, Wong DK, Fung J, Hung IF, Yuen JC, Tong T, Lai CL, Yuen MF.

Hepatol Int. 2012 May 4;7(1):119-126. eCollection 2012 May 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk